Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Survey by TEDDY European Network of Excellence for Paediatric Clinical Research demonstrates potential for Europe-wide trials.

Ruggieri L, Bonifazi D, Landi A, Bonifazi F, Bartoloni F, Costello M, Felisi MG, Gasthuys E, Godo A, Martinon Torres F, Nadal D, Nuytinck L, Rocchi F, Turner M, Ceci A.

Acta Paediatr. 2020 Mar;109(3):607-612. doi: 10.1111/apa.15020. Epub 2019 Oct 13.

PMID:
31532836
2.

Bioremediation of Dichlorodiphenyltrichloroethane (DDT)-Contaminated Agricultural Soils: Potential of Two Autochthonous Saprotrophic Fungal Strains.

Russo F, Ceci A, Pinzari F, Siciliano A, Guida M, Malusà E, Tartanus M, Miszczak A, Maggi O, Persiani AM.

Appl Environ Microbiol. 2019 Oct 16;85(21). pii: e01720-19. doi: 10.1128/AEM.01720-19. Print 2019 Nov 1.

PMID:
31444208
3.

Understanding fungal potential in the mitigation of contaminated areas in the Czech Republic: tolerance, biotransformation of hexachlorocyclohexane (HCH) and oxidative stress analysis.

Russo F, Ceci A, Maggi O, Siciliano A, Guida M, Petrangeli Papini M, Černík M, Persiani AM.

Environ Sci Pollut Res Int. 2019 Aug;26(24):24445-24461. doi: 10.1007/s11356-019-05679-w. Epub 2019 Jun 22.

PMID:
31228071
4.

Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.

de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Della Pasqua O, Tibboel D, Ceci A, de Wildt SN; GAPP consortium.

Trials. 2019 Jun 20;20(1):368. doi: 10.1186/s13063-019-3519-9.

5.

Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol.

Kaguelidou F, Le Roux E, Mangiarini L, Lundin R, de Leeuw TG, Della Pasqua O, Felisi M, Bonifazi D, Tibboel D, Ceci A, de Wildt SN, Alberti C; GAPP consortium.

BMJ Open. 2019 Feb 20;9(2):e023296. doi: 10.1136/bmjopen-2018-023296.

6.

Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.

de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Pasqua OD, Tibboel D, Ceci A, de Wildt SN; GAPP consortium.

Trials. 2019 Jan 15;20(1):49. doi: 10.1186/s13063-018-3169-3. Erratum in: Trials. 2019 Jun 20;20(1):368.

7.

Roles of saprotrophic fungi in biodegradation or transformation of organic and inorganic pollutants in co-contaminated sites.

Ceci A, Pinzari F, Russo F, Persiani AM, Gadd GM.

Appl Microbiol Biotechnol. 2019 Jan;103(1):53-68. doi: 10.1007/s00253-018-9451-1. Epub 2018 Oct 25. Review.

PMID:
30362074
8.

Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey.

Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour C, Otto A, Rastegari M, Berry P.

BMJ Paediatr Open. 2017 Sep 5;1(1):e000170. doi: 10.1136/bmjpo-2017-000170. eCollection 2017.

9.

Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.

Just S, Chenard BL, Ceci A, Strassmaier T, Chong JA, Blair NT, Gallaschun RJ, Del Camino D, Cantin S, D'Amours M, Eickmeier C, Fanger CM, Hecker C, Hessler DP, Hengerer B, Kroker KS, Malekiani S, Mihalek R, McLaughlin J, Rast G, Witek J, Sauer A, Pryce CR, Moran MM.

PLoS One. 2018 Jan 31;13(1):e0191225. doi: 10.1371/journal.pone.0191225. eCollection 2018.

10.

Saprotrophic soil fungi to improve phosphorus solubilisation and release: In vitro abilities of several species.

Ceci A, Pinzari F, Russo F, Maggi O, Persiani AM.

Ambio. 2018 Jan;47(Suppl 1):30-40. doi: 10.1007/s13280-017-0972-0.

11.

Metabolic synergies in the biotransformation of organic and metallic toxic compounds by a saprotrophic soil fungus.

Ceci A, Pinzari F, Riccardi C, Maggi O, Pierro L, Petrangeli Papini M, Gadd GM, Persiani AM.

Appl Microbiol Biotechnol. 2018 Jan;102(2):1019-1033. doi: 10.1007/s00253-017-8614-9. Epub 2017 Nov 14.

PMID:
29138910
12.

Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.

Botzenhardt S, Felisi M, Bonifazi D, Del Vecchio GC, Putti MC, Kattamis A, Ceci A, Wong ICK, Neubert A; DEEP consortium (collaborative group).

Haematologica. 2018 Jan;103(1):e1-e4. doi: 10.3324/haematol.2017.176065. Epub 2017 Oct 27. No abstract available.

13.

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.

Giannuzzi V, Landi A, Bosone E, Giannuzzi F, Nicotri S, Torrent-Farnell J, Bonifazi F, Felisi M, Bonifazi D, Ceci A.

BMJ Open. 2017 Sep 11;7(9):e017358. doi: 10.1136/bmjopen-2017-017358.

14.

Pattern of complications and burden of disease in patients affected by beta thalassemia major.

Bonifazi F, Conte R, Baiardi P, Bonifazi D, Felisi M, Giordano P, Giannuzzi V, Iacono A, Padula R, Pepe A, Caterina Putti M, Ruggieri L, Carlo Del Vecchio G, Filosa A, Maggio A, Ceci A; HTA-THAL Multiregional Registry.

Curr Med Res Opin. 2017 Aug;33(8):1525-1533. doi: 10.1080/03007995.2017.1326890. Epub 2017 Jun 7.

PMID:
28471307
15.

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.

Giannuzzi V, Conte R, Landi A, Ottomano SA, Bonifazi D, Baiardi P, Bonifazi F, Ceci A.

Orphanet J Rare Dis. 2017 Apr 3;12(1):64. doi: 10.1186/s13023-017-0617-1.

16.

The ethical framework for performing research with rare inherited neurometabolic disease patients.

Giannuzzi V, Devlieger H, Margari L, Odlind VL, Ragab L, Bellettato CM, D'Avanzo F, Lampe C, Cassis L, Cortès-Saladelafont E, Cazorla ÁG, Barić I, Cvitanović-Šojat L, Fumić K, Dali CI, Bartoloni F, Bonifazi F, Scarpa M, Ceci A.

Eur J Pediatr. 2017 Mar;176(3):395-405. doi: 10.1007/s00431-017-2852-9. Epub 2017 Jan 16. Review.

17.

Erratum to: Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Cassis L, Cortès-Saladelafont E, Molero-Luis M, Yubero D, González MJ, Ormazábal A, Fons C, Jou C, Sierra C, Ponce EC, Ramos F, Armstrong J, O'Callaghan MM, Casado M, Montero R, Meavilla-Olivas S, Artuch R, Barić I, Bartoloni F, Bellettato CM, Bonifazi F, Ceci A, Cvitanović-Šojat L, Dali CI, D'Avanzo F, Fumic K, Giannuzzi V, Lampe C, Scarpa M, Garcia-Cazorla Á.

Orphanet J Rare Dis. 2016 Nov 3;11(1):147. No abstract available.

18.

Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.

Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP).

Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6.

19.

Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches.

Smania G, Baiardi P, Ceci A, Cella M, Magni P.

CPT Pharmacometrics Syst Pharmacol. 2016 Aug;5(8):402-10. doi: 10.1002/psp4.12092. Epub 2016 Aug 17.

20.

LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.

Fuertig R, Ceci A, Camus SM, Bezard E, Luippold AH, Hengerer B.

Bioanalysis. 2016 Sep;8(18):1903-17. doi: 10.4155/bio-2016-0111. Epub 2016 Aug 15.

21.

Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.

Smania G, Baiardi P, Ceci A, Magni P, Cella M.

CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):305-12. doi: 10.1002/psp4.12083. Epub 2016 Jun 1.

22.

Phenotype MicroArray™ system in the study of fungal functional diversity and catabolic versatility.

Pinzari F, Ceci A, Abu-Samra N, Canfora L, Maggi O, Persiani A.

Res Microbiol. 2016 Nov - Dec;167(9-10):710-722. doi: 10.1016/j.resmic.2016.05.008. Epub 2016 Jun 6. Review.

PMID:
27283363
23.

Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain.

Hu B, Doods H, Treede RD, Ceci A.

Neurosci Lett. 2016 Apr 21;619:162-7. doi: 10.1016/j.neulet.2016.03.019. Epub 2016 Mar 14.

PMID:
26987721
24.

The Italian multiregional thalassemia registry: Centers characteristics, services, and patients' population.

Conte R, Ruggieri L, Gambino A, Bartoloni F, Baiardi P, Bonifazi D, Bonifazi F, Felisi M, Giannuzzi V, Padula R, Pepe A, Putti MC, Del Vecchio GC, Maggio A, Filosa A, Iacono A, Mangiarini L, Ceci A.

Hematology. 2016 Aug;21(7):415-24. doi: 10.1080/10245332.2015.1101971. Epub 2016 Feb 22.

PMID:
26863102
25.

Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase.

Fuertig R, Azzinnari D, Bergamini G, Cathomas F, Sigrist H, Seifritz E, Vavassori S, Luippold A, Hengerer B, Ceci A, Pryce CR.

Brain Behav Immun. 2016 May;54:59-72. doi: 10.1016/j.bbi.2015.12.020. Epub 2015 Dec 24.

PMID:
26724575
26.

Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Cassis L, Cortès-Saladelafont E, Molero-Luis M, Yubero D, González MJ, Ormazábal A, Fons C, Jou C, Sierra C, Castejon Ponce E, Ramos F, Armstrong J, O'Callaghan MM, Casado M, Montero R, Meavilla-Olivas S, Artuch R, Barić I, Bartoloni F, Bellettato CM, Bonifazi F, Ceci A, Cvitanović-Šojat L, Dali CI, D'Avanzo F, Fumic K, Giannuzzi V, Lampe C, Scarpa M, Garcia-Cazorla Á.

Orphanet J Rare Dis. 2015 Dec 30;10:164. doi: 10.1186/s13023-015-0376-9. Review. Erratum in: Orphanet J Rare Dis. 2016 Nov 3;11(1):147.

27.

Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.

Botzenhardt S, Sing CW, Wong IC, Chan GC, Wong LY, Felisi M, Rascher W, Ceci A, Neubert A.

Curr Drug Saf. 2016;11(2):137-44.

PMID:
26419768
28.

Phosphatase-mediated bioprecipitation of lead by soil fungi.

Liang X, Kierans M, Ceci A, Hillier S, Gadd GM.

Environ Microbiol. 2016 Jan;18(1):219-31. doi: 10.1111/1462-2920.13003. Epub 2015 Sep 3.

PMID:
26235107
29.

CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway.

Cathomas F, Fuertig R, Sigrist H, Newman GN, Hoop V, Bizzozzero M, Mueller A, Luippold A, Ceci A, Hengerer B, Seifritz E, Fontana A, Pryce CR.

Brain Behav Immun. 2015 Nov;50:125-140. doi: 10.1016/j.bbi.2015.06.184. Epub 2015 Jul 11.

PMID:
26173174
30.

Biotransformation of β-hexachlorocyclohexane by the saprotrophic soil fungus Penicillium griseofulvum.

Ceci A, Pierro L, Riccardi C, Pinzari F, Maggi O, Persiani AM, Gadd GM, Petrangeli Papini M.

Chemosphere. 2015 Oct;137:101-7. doi: 10.1016/j.chemosphere.2015.05.074. Epub 2015 Jun 10.

PMID:
26071688
31.

Clinical Trial Application in Europe: What Will Change with the New Regulation?

Giannuzzi V, Altavilla A, Ruggieri L, Ceci A.

Sci Eng Ethics. 2016 Apr;22(2):451-66. doi: 10.1007/s11948-015-9662-0. Epub 2015 Jun 3.

PMID:
26037896
32.

Fungal Bioweathering of Mimetite and a General Geomycological Model for Lead Apatite Mineral Biotransformations.

Ceci A, Kierans M, Hillier S, Persiani AM, Gadd GM.

Appl Environ Microbiol. 2015 Aug;81(15):4955-64. doi: 10.1128/AEM.00726-15. Epub 2015 May 15.

33.

Clinical evaluation with 18 months follow-up of new PTTM enhanced dental implants in maxillo-facial post-oncological patients.

Papi P, Jamshir S, Brauner E, Di Carlo S, Ceci A, Piccoli L, Pompa G.

Ann Stomatol (Roma). 2015 Feb 9;5(4):136-41. eCollection 2014 Oct-Dec.

34.

Uranium phosphate biomineralization by fungi.

Liang X, Hillier S, Pendlowski H, Gray N, Ceci A, Gadd GM.

Environ Microbiol. 2015 Jun;17(6):2064-75. doi: 10.1111/1462-2920.12771. Epub 2015 Mar 10.

PMID:
25580878
35.

Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.

Bartolozzi A, Cirillo PF, Berry AK, Hickey ER, Thomson DS, Wu L, Zindell R, Albrecht C, Ceci A, Gemkow MJ, Nagaraja NV, Romig H, Sauer A, Riether D.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):587-92. doi: 10.1016/j.bmcl.2014.12.031. Epub 2014 Dec 17.

PMID:
25575658
36.

Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.

Riether D, Zindell R, Wu L, Betageri R, Jenkins JE, Khor S, Berry AK, Hickey ER, Ermann M, Albrecht C, Ceci A, Gemkow MJ, Nagaraja NV, Romig H, Sauer A, Thomson DS.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):581-6. doi: 10.1016/j.bmcl.2014.12.019. Epub 2014 Dec 13.

PMID:
25556092
37.

Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines.

Ruggieri L, Giannuzzi V, Baiardi P, Bonifazi F, Davies EH, Giaquinto C, Bonifazi D, Felisi M, Chiron C, Pressler R, Rabe H, Whitaker MJ, Neubert A, Jacqz-Aigrain E, Eichler I, Turner MA, Ceci A; GRiP Consortium.

Eur J Pediatr. 2015 Apr;174(4):481-91. doi: 10.1007/s00431-014-2398-z. Epub 2014 Sep 23.

38.

Transformation of vanadinite [Pb5 (VO4 )3 Cl] by fungi.

Ceci A, Rhee YJ, Kierans M, Hillier S, Pendlowski H, Gray N, Persiani AM, Gadd GM.

Environ Microbiol. 2015 Jun;17(6):2018-34. doi: 10.1111/1462-2920.12612. Epub 2014 Oct 29.

PMID:
25181352
39.

Tramadol reduces anxiety-related and depression-associated behaviors presumably induced by pain in the chronic constriction injury model of neuropathic pain in rats.

Caspani O, Reitz MC, Ceci A, Kremer A, Treede RD.

Pharmacol Biochem Behav. 2014 Sep;124:290-6. doi: 10.1016/j.pbb.2014.06.018. Epub 2014 Jun 27.

PMID:
24974768
40.

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassarà F, Harmatz P, Wood J, Gluud C.

Blood Cells Mol Dis. 2011 Oct 15;47(3):166-75. doi: 10.1016/j.bcmd.2011.07.002. Epub 2011 Aug 16. Review.

PMID:
21843958
41.

[Use, implementation and impact of the TEDDY network in Europe].

Mellado Peña MJ, Piñeiro Pérez R, Medina Claros AF, Ceci A.

Farm Hosp. 2012 Mar-Apr;36(2):109-10. doi: 10.1016/j.farma.2011.01.004. Epub 2011 Jul 23. Spanish. No abstract available.

PMID:
21783396
42.

The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients.

Ceci A, Mangiarini L, Felisi M, Bartoloni F, Ciancio A, Capra M, D'Ascola D, Cianciulli P, Filosa A.

Anemia. 2011;2011:435683. doi: 10.1155/2011/435683. Epub 2011 Jun 5.

43.

Impact of the new european paediatric regulatory framework on ethics committees: overview and perspectives.

Altavilla A, Manfredi C, Baiardi P, Dehlinger-Kremer M, Galletti P, Pozuelo AA, Chaplin J, Ceci A.

Acta Paediatr. 2012 Jan;101(1):e27-32. doi: 10.1111/j.1651-2227.2011.02401.x. Epub 2011 Jul 23. Review.

PMID:
21732978
44.

Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases.

Scarpa M, Ceci A, Tomanin R, Mincarone P, Begley D.

EPMA J. 2011 Jun;2(2):231-9. doi: 10.1007/s13167-011-0081-2. Epub 2011 May 1.

45.

Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age.

Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, Ceci A, Sturkenboom MC; TEDDY European Network of Excellence.

Br J Clin Pharmacol. 2011 Jun;71(6):943-50. doi: 10.1111/j.1365-2125.2010.03860.x.

46.

Innovative study design for paediatric clinical trials.

Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A; TEDDY Network of Excellence.

Eur J Clin Pharmacol. 2011 May;67 Suppl 1:109-15. doi: 10.1007/s00228-011-0990-y. Epub 2011 Feb 8. Review.

PMID:
21301825
47.

Assessment of pediatric asthma drug use in three European countries; a TEDDY study.

Sen EF, Verhamme KM, Neubert A, Hsia Y, Murray M, Felisi M, Giaquinto C, 't Jong GW, Picelli G, Baraldi E, Nicolosi A, Ceci A, Wong IC, Sturkenboom MC; TEDDY European Network of Excellence.

Eur J Pediatr. 2011 Jan;170(1):81-92. doi: 10.1007/s00431-010-1275-7. Epub 2010 Sep 2.

48.

The European paediatric legislation: benefits and perspectives.

Rocchi F, Paolucci P, Ceci A, Rossi P.

Ital J Pediatr. 2010 Aug 17;36:56. doi: 10.1186/1824-7288-36-56.

49.

Peritonitis in type 2 diabetes mellitus due to Ochrobactrum anthropi complicating automated peritoneal dialysis.

Sepe V, Esposito P, Sacco L, Ceci A, Magrassi A, Negri MT, Libetta C, Dal Canton A.

Acta Diabetol. 2010 Dec;47(4):341-4. doi: 10.1007/s00592-010-0204-6. Epub 2010 Jun 19. Erratum in: Acta Diabetol. 2011 Sep;48(3):255. Canton, A D [corrected to Dal Canton, Antonio].

PMID:
20563608
50.

The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands.

Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, Giaquinto C, Ceci A, Sturkenboom M, Wong IC; TEDDY Network of Excellence.

Pharmacol Res. 2010 Sep;62(3):243-8. doi: 10.1016/j.phrs.2010.04.006. Epub 2010 May 6.

PMID:
20451614

Supplemental Content

Support Center